Topic:

Companion Diagnostics

Latest Headlines

Latest Headlines

Roche's Ventana expands infrastructure in Arizona

Roche's Ventana Medical Systems is building a new distribution center in Arizona and plans to generate additional jobs in the process.

Flagship Biosciences and Sarepta will automate muscular dystrophy biomarker detection

Tissue-based companion diagnostics company Flagship Biosciences said it will join with Sarepta Therapeutics to automate and quicken measurement of a key biomarker for muscular dystrophy.

Illumina, AstraZeneca, Janssen and Sanofi to pursue universal companion Dx test

Illumina has inked deals with three major Big Pharma companies with a goal of developing a universal gene-sequencing companion diagnostic test system focused on cancer.

Qiagen sees blood cancer biomarker Dx potential in University of Tokyo patents

Qiagen aims to develop new tests to target blood cancer patients who would benefit most from a particular treatment that hits a specific gene mutation. The plan could lead to new companion diagnostic tests for related drugs now under development.

Roche and Merck KGaA team on a multicancer companion diagnostic test

Roche's Ventana Medical Systems will develop a companion diagnostic test with Germany's Merck KGaA that can be used for many different cancer types.

Roche lends Dx tech to Ferring for an infertility treatment

Roche is lending its diagnostic technology to Ferring Pharmaceuticals to develop a personalized treatment for female infertility.

Cancer Dx company Definiens adds $20.4M venture round

Definiens secured financing to grow its existing imaging-analysis business and to expand into tissue diagnostics. New investor Wellington Partners led the €15 million ($20.4 million) financing and joined the board.

NanoString to produce companion test for Celgene's blockbuster cancer drug Revlimid

Seattle's NanoString Technologies stands to make up to $45 million if it can come up with a successful companion diagnostic test to screen for a subset of lymphoma patients who will benefit from Celgene's blockbuster drug Revlimid.

Almac at ASCO: Dx spots ovarian cancer patients for whom Roche's Avastin would hurt

Almac Group saved some stellar news for the 2014 ASCO Annual Meeting in Chicago. The U.K. life sciences contract manufacturer said it validated a new diagnostic test that spots a subset of ovarian cancer patients with greater survival odds following standard chemotherapy who should avoid a specific Roche drug. 

Qiagen and Lilly continue successful string of diagnostics partnerships

Qiagen and Eli Lilly have joined forces for their fourth companion diagnostics project, building on the momentum of past collaborations to develop assay panels for cancer.